Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07399067 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 96 to 120 · Start date changed from estimate of Jan 30, 2026 to Feb 6, 2026 · Interventions: IBI3002 (Drug), Placebo (Drug) to Dupilumab (Drug), IBI3002 (Drug), Placebo (Drug) · 4 morev2 Show 7 more changesShow less
    • Enrollment target: 96 to 120
    • Start date changed from estimate of Jan 30, 2026 to Feb 6, 2026
    • Interventions: IBI3002 (Drug), Placebo (Drug) to Dupilumab (Drug), IBI3002 (Drug), Placebo (Drug)
    • Eligibility criteria expanded, about 20 words
    • Study description expanded, about 10 words
    • Site details revised
    • Study arms: 5 to 6

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).
Trial Details
NCT Number NCT07399067
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Atopic Dermatitis
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov